Here’s What Will Fuel Inogen’s (INGN) Future Growth

Core Insights - Jacob Fund's third-quarter 2025 investor letter indicates a continued market recovery with major equity indexes reaching new all-time highs, driven by stabilized trade policies and a focus on fundamentals [1] - The fund anticipates a new productivity cycle that will enhance profit margins and earnings growth, while remaining focused on companies poised for earnings growth and improved valuation multiples [1] Company Insights: Inogen, Inc. (NASDAQ:INGN) - Inogen, Inc. is a medical device company specializing in respiratory health products, with a one-month return of -1.14% and a 52-week loss of 27.02%, closing at $6.94 per share with a market capitalization of $188.41 million as of December 5, 2025 [2] - The company has faced challenges due to mismanagement and competition but has stabilized recently, retaining a dominant market share and benefiting from new management that has improved profitability and innovation [3] - Inogen is not among the 30 most popular stocks among hedge funds, with 21 hedge fund portfolios holding its shares at the end of the third quarter, an increase from 20 in the previous quarter [4]